Navigation Links
New long-term antimicrobial catheter developed
Date:9/3/2012

A novel antimicrobial catheter that remains infection-free for up to twelve weeks could dramatically improve the lives of long-term catheter users. The scientists who have developed the new technology are presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

Researchers at the University of Nottingham have developed a catheter that can kill most urinary bacteria, including most strains of Proteus bacteria the most common cause of catheter infections. Importantly the antimicrobial catheter retains its activity for between six to twelve weeks, making it suitable for long-term use, unlike existing commercial anti-infection catheters.

Urinary catheters are commonly used to manage incontinence in the elderly or individuals who have suffered long-term spinal cord injury. All catheters become infected after a couple of weeks and Proteus bacteria are responsible for up to 40% of these infections. The bacterium sticks to catheter surfaces and breaks down urea, causing the pH of urine to rise. This causes deposits of mineral crystals in the catheter which blocks it, preventing drainage. If unnoticed, catheter blockage can lead to kidney and bloodstream infections, which ultimately may result in potentially fatal septic shock.

This new antimicrobial catheter has significant advantages over existing solutions, explained Dr Roger Bayston who is leading the development. "Commercial 'anti-infection' catheters are active for only a few days and are not suitable for long-term use. There is an urgent need for an antimicrobial catheter that is suitable for long-term use. Our catheter uses patented technology that does not involve any coatings which extends its antimicrobial activity. The process involves introducing antimicrobial molecules into the catheter material after manufacture, so that they are evenly distributed throughout it, yet can move through the material to replenish those washed away from the surface."

There are 100 million catheter users worldwide whose lives can be severely disrupted by illness from repeat infections and side-effects from antibiotics. "The catheter technology has proven benefit in other medical settings and has the potential to be the solution to recurrent infections in long-term catheter users, which will improve quality of life of these individuals. In addition, reducing the need to frequently change catheters and treat infections would represent huge financial savings to the NHS," explained Dr Bayston.


'/>"/>

Contact: Laura Udakis
l.udakis@sgm.ac.uk
44-079-908-26696
Society for General Microbiology
Source:Eurekalert

Related biology news :

1. Is long-term weight loss possible after menopause?
2. Study shows long-term effects of radiation in pediatric cancer patients
3. Model forecasts long-term impacts of forest land-use decisions
4. Long-term preservation: Pensoft Publishers partner with the CLOCKSS Archive
5. Sexual reproduction brings long-term benefits, study shows
6. Long-term research reveals causes and consequences of environmental change
7. Antimicrobials from personal care products found in statewide survey of Minnesotas rivers and lakes
8. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
9. Electronic nose prototype developed
10. Composite nanofibers developed by Penn scientists next chapter in orthopaedic biomaterials
11. Grassroots approach to conservation developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... 2016 Australian-US drug discovery and development company, Novogen ... of a new Chairman, Mr John O,Connor , and ... James Garner , has also been formally ... Acting CEO, Mr Iain Ross , will resume his ... James Garner , has also been formally appointed to ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... ... , ... Shimadzu Scientific Instruments will showcase several new products, ... sessions, and present on the analysis of mycotoxins and medical cannabis at the ... at the Georgia World Congress Center in Atlanta, Georgia. , Attendees should ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology: